Physician profile

George B Lantz

Pain Medicine (Anesthesiology) · Lebanon, NH

NPI 1972565422

$4,679.20

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$34.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pacira Therapeutics, INC. $2,549.00 2019-2021
Abbott Laboratories $1,562.24 2019-2021
Nevro Corp. $164.41 2019
Avanos Medical $134.49 2019
Stimwave Technologies Incorporated $134.00 2019
Ambu INC. $37.18 2022
Pacira Pharmaceuticals Incorporated $34.56 2024 Iovera
Boston Scientific Corporation $26.74 2019
Bioventus LLC $21.43 2019
Relievant Medsystems, INC. $15.15 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George B Lantz

$4,679.20

in general payments reported 2019-2025

Years
2019-2024
Top company
Pacira Therapeutics, INC.

https://glasscript.com/doctor/89470/george-b-lantz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.